nuclear receptor subfamily 1 group D member 2Genealiases: BD73 · EAR-1R · REVERBB · REVERBbeta · RVR
Q-omics provides the consensus-scored NR1D2 profile across patient tissues and cancer cell-line models. NR1D2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NR1D2 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, NR1D2 RNA expression shows 20,699 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KIRC, and ACC as cancer lineages where NR1D2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NR1D2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NR1D2 survival associations across molecular data types. NR1D2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NR1D2 RNA expression–survival associations across cancer types. High NR1D2 expression shows unfavorable associations in ACC, but favorable associations in HNSC, SKCM, KIRC, LGG and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NR1D2 RNA expression.
This table summarizes NR1D2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NR1D2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NR1D2 shows lower tumor expression in KIRC, UCEC, BRCA, KIRP and THCA and higher tumor expression in LIHC. The KIRC box plot shows higher NR1D2 RNA expression in normal versus tumor tissue (log2 FC = −0.919, t-test p < 0.001).
This table shows molecular features associated with NR1D2 in patient tissues and cancer cell lines. In patient samples, NR1D2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NR1D2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
